Home / Business and Economy / Neuland Labs Profit Plummets 60% Amid Revenue Slump
Neuland Labs Profit Plummets 60% Amid Revenue Slump
9 Feb
Summary
- Net profit fell 60% to ₹40.6 crore in Q3 FY24.
- Revenue declined 10.5% year-on-year to ₹439.7 crore.
- EBITDA margin contracted by 410 basis points to 17.6%.
Drug firm Neuland Laboratories Ltd. experienced a substantial financial downturn in the third quarter of the current financial year, which concluded on February 9, 2026. The company's net profit saw a dramatic 60% decrease, falling to ₹40.6 crore from ₹101.6 crore reported during the corresponding period last year.
Revenue for the quarter also reflected a downward trend, with a 10.5% year-on-year decline to ₹439.7 crore. Sequentially, revenue dropped by 14.8%. Earnings before interest, tax, depreciation, and amortisation (EBITDA) declined by 10.5% year-on-year to ₹77.3 crore, and the EBITDA margin contracted by 410 basis points, settling at 17.6% from 21.7%.
In a strategic move during the December quarter, Neuland approved a capital expenditure of ₹189 crore to establish a new research and development centre in Hyderabad. Meanwhile, shares of Neuland Laboratories closed at ₹13,030 apiece on the NSE, marking a 1.30% decrease on the day.
